Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
mi
from
Atlanta, GA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Idaho Urologic Institute - Meridian
mi
from
Meridian, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Idaho Urologic Institute - Meridian
mi
from
Meridian, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute-Twin Falls
mi
from
Twin Falls, ID
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute-Twin Falls
mi
from
Twin Falls, ID
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Northwestern Medicine Cancer Center Delnor
mi
from
Geneva, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Northwestern Medicine Cancer Center Delnor
mi
from
Geneva, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Reid Health
mi
from
Richmond, IN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Kansas Institute of Medicine Cancer and Blood Center
mi
from
Lenexa, KA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Kansas Institute of Medicine Cancer and Blood Center
mi
from
Lenexa, KA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Minimally Invasive Surgery Hospital
mi
from
Lenexa, KA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Minimally Invasive Surgery Hospital
mi
from
Lenexa, KA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Menorah Medical Center
mi
from
Overland Park, KA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Menorah Medical Center
mi
from
Overland Park, KA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Luke's South Hospital
mi
from
Overland Park, KA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Luke's South Hospital
mi
from
Overland Park, KA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Bronson Battle Creek
mi
from
Battle Creek, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Bronson Battle Creek
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Brighton
mi
from
Brighton, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Brighton
mi
from
Brighton, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Brighton
mi
from
Brighton, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Brighton
mi
from
Brighton, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Canton
mi
from
Canton, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Caro Cancer Center
mi
from
Caro, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Caro Cancer Center
mi
from
Caro, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Chelsea
mi
from
Chelsea, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Chelsea
mi
from
Chelsea, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Chelsea
mi
from
Chelsea, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Chelsea
mi
from
Chelsea, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Consultants-Clarkston
mi
from
Clarkston, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Consultants-Clarkston
mi
from
Clarkston, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Newland Medical Associates-Clarkston
mi
from
Clarkston, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Newland Medical Associates-Clarkston
mi
from
Clarkston, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Genesee Cancer & Blood Disease Treatment Center, PC
mi
from
Flint, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Genesee Cancer & Blood Disease Treatment Center, PC
mi
from
Flint, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Genesee Hematology Oncology PC
mi
from
Flint, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Genesee Hematology Oncology PC
mi
from
Flint, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Allegiance Health
mi
from
Jackson, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Click here to add this to my saved trials